Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260359 · ClinicalTrials.gov registry record · Phase 2
Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
A Phase 2 study of Sunburn, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 1
- Study location
NCT05260359 is a Phase 2 study of Sunburn that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 224 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05260359, a Phase 2 study of Sunburn, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
Conditions Studied
Interventions
- OTHER 0.9% Saline
- DRUG 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation
- DRUG 6% Bemotrizinol (BEMT) dispersion in petrolatum
- OTHER Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT
- OTHER Petrolatum vehicle
Study Locations (1)
New Jersey
- Eurofins | CRL, Inc. - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2022-04-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05260359
The ClinicalTrials.gov registry entry for NCT05260359 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is dsm-firmenich Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sunburn appearing as the primary indexed condition, and to 5 interventions - of which 0.9% Saline is the first listed.
NCT05260359 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05260359 about?
NCT05260359 is a clinical study titled "Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol". The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
What is the current status of trial NCT05260359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2022-02-23. Estimated completion is 2022-04-08.
What conditions does trial NCT05260359 study?
This clinical trial studies the following conditions: Sunburn.
What interventions are being tested in trial NCT05260359?
The interventions under investigation include: 0.9% Saline (OTHER), 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (DRUG), 6% Bemotrizinol (BEMT) dispersion in petrolatum (DRUG), Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (OTHER), Petrolatum vehicle (OTHER).
Who is sponsoring clinical trial NCT05260359?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05260359 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sunburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.